Multiorgan Pathology in Chronic Obstructive Pulmonary Disease (COPD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-09-30

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is increasing evidence in the literature that COPD should not be considered as a localised pulmonary disorder but as a systemic disease involving pathology in several extra pulmonary tissues. Well characterized systemic features are a chronic low grade systemic inflammation, altered body composition and a skeletal muscle fibre type shift. There are indications that an absolute or relative increase of fat mass puts COPD patients at increased risk for cardiovascular pathology while muscle atrophy is associated with a high prevalence of osteoporosis and with impaired physical function. The origin of systemic inflammation is poorly understood. Both endogenous and exogenous risk factors contribute to systemic inflammation and extra-pulmonary manifestations of COPD.

Overall objective of study 3:

To compare the pattern and severity of the systemic inflammatory profile in relation to skeletal muscle weakness and cardiovascular risk profile in COPD patients with mild to moderate disease compared to non-susceptible smokers.

Specific objectives:

1. To study the relative contribution of pulmonary and extra pulmonary factors on exercise capacity, skeletal muscle function and health status
2. To relate diet, physical activity and cardiovascular risk factors to body composition, skeletal muscle function and exercise capacity status
3. To study the influence of the emphysema phenotype on extra pulmonary pathology in COPD
4. To study muscle fibre type size and composition and to relate muscle oxidative phenotype with insulin sensitivity, inflammation (local and systemic) and molecular signatures of oxidative energy and protein metabolism.

Study design:

Cross-sectional study. Healthy smoking subjects and COPD patients will undergo extensive clinical, metabolic and inflammatory assessment at the university clinics in Groningen, Maastricht and CIRO Horn.

Study population:

Totally 60 subjects will be included

* 30 healthy subjects who after 20 pack years smoking have no signs of COPD (age 40-75 years)
* 30 COPD patients with GOLD stage II (age 40-75 years)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Systemic Inflammation in Chronic Obstructive Pulmonary Disease (COPD)

NCT00850863

Chronic Obstructive Pulmonary Disease

UNKNOWN

Micro-environment Involvement in Muscle Alteration Induced

NCT04448626

Chronic Obstructive Pulmonary Disease Exacerbations Skeletal Muscle Atrophy

COMPLETED

Respiratory Muscles in End-stage Lung Disease: Pathophysiological Processes & Clinical Consequences

NCT06935825

COPD

NOT_YET_RECRUITING

Repair, Remodeling and Regeneration of the Bronchial Epithelium of COPD Patients

NCT02354677

Heathy Volunteers Smokers COPD

COMPLETED NA

EFFECT OF SMOKING ON MUCUS HYPERSECRETION MECHANISMS IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE

NCT01947218

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary study parameters/outcome of the study:

1. Smoking history and behaviour, diet and physical activity level assessed by questionnaire
2. Extensive lung function and CT scanning of the lung, ECG
3. Candidate genes for muscle dysfunction and CVD risk
4. Body composition (BIA, waist-hip ratio, DEXA-scan)
5. Systemic inflammation
6. Advanced Glycosylated Endproduct (AGE)
7. Glucose tolerance test
8. Risk factors of metabolic syndrome
9. 6 minute walking distance
10. Handgrip strength
11. Skeletal muscle function by isokinetic dynamometry
12. Physical activity level and pattern by accelerometry
13. Muscle oxidative phenotype, fibre cross-sectional area and molecular signatures obtained in vastus lateralis muscle biopsies before and after incremental cycle ergometry

Nature and extent of the burden and risks associated with participation, benefit and group relatedness (if applicable):

* Totally 22 hours will be spend in the hospital during 3 visits
* CT-scanning of the lung is associated with a radiation burden of 0.8-1.6 mSv (dependent of body weight)
* 50 ml peripheral blood (v. cubiti)
* Muscle biopsy may be associated with temporary pain and haematoma
* Drawing of arterial blood from the radial artery rarely leads to bleeding and transitory nerve damage (numb feeling in wrist/hand area).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

• 30 healthy subjects with 20 pack years smoking who have no signs of COPD (age 40-75 years)

No interventions assigned to this group

2

• 30 COPD patients with GOLD stage II (age 40-75 years)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 40-75 years
* Age, pack years, FEV1/FVC and FEV1% predicted must fit in one of 2 groups of table 4.3
* Physically and mentally able to undergo the total study protocol
* Written informed consent

Exclusion Criteria

* Participation in another study
* Alpha-1-antitrypsin deficiency
* Selected grade 1-3 co-morbidity listed in the ACE-27
* Active pulmonary infection like tuberculosis, pneumonia, flue, tracheobronchitis
* Active extra-pulmonary infection like hepatitis A-C, cystitis, gastroenteritis etc.
* Pulmonary diseases like sarcoidosis, IPF, silicosis, hypersensitivity pneumonitis, asthma
* Life threatening diseases like carcinoma, AIDS (including HIV+), acute leukemia etc.
* Medication that may affect the results of the study: NSAID's, immunosuppressive agents like prednisolon, methotrexate, azathioprine, sintrom tablets, askal
* Antibiotic or prednisolon use in the past 2 months

Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes